Eitan Friedman

List of Publications by Citations

212 papers	9,264 citations	41 h-index	92 g-index
222 ext. papers	11,014 ext. citations	6.9 avg, IF	4.94 L-index

#	Paper	IF	Citations
212	Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. *New England Journal of Medicine*, **1991**, 325, 1688-95	59.2	1530
211	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
210	Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. *New England Journal of Medicine*, **2001**, 345, 235-40	59.2	320
209	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
208	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
207	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. *International Journal of Cancer*, **2008**, 122, 2017-22	7.5	268
206	Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2002**, 94, 1773-9	9.7	266
205	Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 4340-5	11.5	256
204	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *American Journal of Human Genetics*, **2008**, 82, 937-48	11	218
203	Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. *Circulation*, **2001**, 103, 2822-7	16.7	217
202	Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 14205-10	11.5	216
201	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
200	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *American Journal of Human Genetics*, **2007**, 81, 1186-200	11	204
199	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
198	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
197	Abraham's children in the genome era: major Jewish diaspora populations comprise distinct genetic clusters with shared Middle Eastern Ancestry. *American Journal of Human Genetics*, **2010**, 86, 850-9	11	181
196	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177

195	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. *Nature Genetics*, **2015**, 47, 987-995	36.3	162
194	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. *European Urology*, **2014**, 66, 489-99	10.2	156
193	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
192	The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. *Gynecologic Oncology*, **2007**, 104, 7-10	4.9	116
191	Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women. *International Journal of Cancer*, **2010**, 127, 589-97	7.5	104
190	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
189	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
188	Second international consensus guidelines for breast cancer in young women (BCY2). *Breast*, **2016**, 26, 87-99	3.6	84
187	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. *European Urology*, **2019**, 76, 831-842	10.2	78
186	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
185	Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 3770-4	11.5	74
184	Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. *Cancer Letters*, **2007**, 257, 236-43	9.9	74
183	Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. *Oncologist*, **2017**, 22, 804-810	5.7	65
182	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
181	BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. *Fertility and Sterility*, **2015**, 104, 1162-7	4.8	62
180	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. *Seminars in Oncology*, **2017**, 44, 187-197	5.5	60
179	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
178	Lessons learned--resolving the enigma of genetic factors in IBS. *Nature Reviews Gastroenterology and Hepatology*, **2016**, 13, 77-87	24.2	55

177	Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. *JAMA Neurology*, **2015**, 72, 58-65	17.2	54
176	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
175	Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. *Human Mutation*, **2000**, 16, 491-501	4.7	48
174	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
173	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
172	Comparative genomic hybridization analysis of nonfunctioning pituitary tumors. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 1801-5	5.6	42
171	CHEK2*1100delC and male breast cancer risk in Israel. *International Journal of Cancer*, **2004**, 108, 479-80	7.5	41
170	Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. *Breast Cancer Research*, **2006**, 8, R15	8.3	40
169	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. *Nature Genetics*, **2020**, 52, 494-504	36.3	39
168	Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. *Fertility and Sterility*, **2015**, 103, 1305-12	4.8	36
167	Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. *Breast Cancer Research and Treatment*, **2016**, 157, 157-65	4.4	36
166	Genotype phenotype correlations in Israeli colorectal cancer patients. *International Journal of Cancer*, **2005**, 114, 58-73	7.5	35
165	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
164	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
163	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
162	Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. *European Journal of Human Genetics*, **2013**, 21, 212-6	5.3	32
161	Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2009**, 116, 195-200	4.4	32
160	Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes. *Clinical Endocrinology*, **1997**, 47, 707-12	3.4	32

159	BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. *International Journal of Gynecological Cancer*, **2010**, 20, 1148-53	3.5	31
158	Genetic and biochemical analyses of Israeli osteogenesis imperfecta patients. *Human Mutation*, **2004**, 23, 399-400	4.7	31
157	Inter- and intra-lesional molecular heterogeneity of oral leukoplakia. *Oral Oncology*, **2015**, 51, 178-81	4.4	28
156	Could the 185delAG BRCA1 Mutation Be an Ancient Jewish Mutation?. *European Journal of Human Genetics*, **1997**, 5, 413-416	5.3	28
155	Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers. *Breast Cancer Research and Treatment*, **2013**, 138, 753-60	4.4	27
154	Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. *Familial Cancer*, **2012**, 11, 483-91	3	27
153	Genetic analysis of familial colorectal cancer in Israeli Arabs. *Human Mutation*, **2003**, 21, 446-7	4.7	27
152	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
151	Genetic analyses of male breast cancer in Israel. *Genetic Testing and Molecular Biomarkers*, **2000**, 4, 313-7		26
150	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
149	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. *Breast Cancer Research*, **2016**, 18, 112	8.3	25
148	Cutaneous malignant melanoma and Parkinson disease: Common pathways?. *Annals of Neurology*, **2016**, 80, 811-820	9.4	25
147	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
146	Microvesicle Proteomic Profiling of Uterine Liquid Biopsy for Ovarian Cancer Early Detection. *Molecular and Cellular Proteomics*, **2019**, 18, 865-875	7.6	25
145	Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. *Breast Cancer Research and Treatment*, **2011**, 127, 489-95	4.4	24
144	Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. *Familial Cancer*, **2015**, 14, 383-91	3	23
143	Functional polymorphisms in the P2X7 receptor gene are associated with stress fracture injury. *Purinergic Signalling*, **2016**, 12, 103-13	3.8	23
142	The polymorphic CAG repeat in the androgen receptor gene in Jewish Israeli women with endometrial carcinoma. *Cancer*, **2001**, 92, 1190-4	6.4	22

141	The I1307K APC polymorphism: prevalence in non-Ashkenazi Jews and evidence for a founder effect. *Genetic Testing and Molecular Biomarkers*, **2001**, 5, 141-6		22
140	Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. *European Journal of Human Genetics*, **2000**, 8, 590-6	5.3	22
139	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2016**, 157, 319-327	4.4	22
138	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22
137	The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers. *Cancer Genetics*, **2016**, 209, 70-4	2.3	21
136	The Tyr978X BRCA1 Mutation in Non-Ashkenazi Jews: Occurrence in High-Risk Families, General Population and Unselected Ovarian Cancer Patients. *Public Health Genomics*, **2001**, 4, 50-55	1.9	21
135	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
134	Bloom syndrome and Fanconi© anemia: rate and ethnic origin of mutation carriers in Israel. *Israel Medical Association Journal*, **2002**, 4, 95-7	0.9	20
133	Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. *Breast Cancer Research and Treatment*, **2014**, 147, 113-8	4.4	19
132	Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma. *Neurology: Genetics*, **2016**, 2, e70	3.8	19
131	Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel. *Breast Cancer Research and Treatment*, **2012**, 133, 1153-7	4.4	18
130	The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients. *Gynecologic Oncology*, **2010**, 119, 511-5	4.9	18
129	Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation. *Breast Cancer Research and Treatment*, **2011**, 129, 557-63	4.4	17
128	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
127	Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information. *American Journal of Medical Genetics Part A*, **2002**, 111, 147-51		16
126	Common origin of the I1307K APC polymorphism in Ashkenazi and non-Ashkenazi Jews. *European Journal of Human Genetics*, **1999**, 7, 555-9	5.3	16
125	Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers. *Cancer*, **2019**, 125, 698-703	6.4	16
124	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15

123	Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. *Movement Disorders*, **2019**, 34, 1392-1398	7	15
122	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
121	Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients. *Genetical Research*, **2014**, 96, e002	1.1	15
120	Molecular analyses of the vasopressin type 2 receptor and aquaporin-2 genes in Brazilian kindreds with nephrogenic diabetes insipidus. *Human Mutation*, **1999**, 14, 233-9	4.7	15
119	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. *European Journal of Cancer*, **2021**, 146, 30-47	7.5	15
118	The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. *Human Mutation*, **2019**, 40, e1-e23	4.7	14
117	Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel. *Breast Cancer Research and Treatment*, **2016**, 155, 133-8	4.4	14
116	The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. *Cancer Genetics*, **2016**, 209, 50-2	2.3	14
115	Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models. *Genetical Research*, **2013**, 95, 174-7	1.1	14
114	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
113	The In Vitro and In Vivo Antiangiogenic Effects of Flavokawain B. *Phytotherapy Research*, **2017**, 31, 1607-1613	6.7	13
112	Prophylactic oophorectomy: clinical considerations. *Journal of Surgical Oncology*, **2000**, 19, 20-7		13
111	Prenatal diagnosis of a novel COL1A1 mutation in osteogenesis imperfecta type I carried through full term pregnancy. *Prenatal Diagnosis*, **2000**, 20, 876-80	3.2	12
110	The Genetics of Bene Israel from India Reveals Both Substantial Jewish and Indian Ancestry. *PLoS ONE*, **2016**, 11, e0152056	3.7	12
109	Spectrum of germline mutations in smokers and non-smokers in Brazilian non-small-cell lung cancer (NSCLC) patients. *Carcinogenesis*, **2017**, 38, 1112-1118	4.6	11
108	Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models. *International Journal of Cancer*, **2018**, 143, 179-183	7.5	11
107	GREM1 germline mutation screening in Ashkenazi Jewish patients with familial colorectal cancer. *Genetical Research*, **2015**, 97, e11	1.1	11
106	Germline mutations in RAD51C in Jewish high cancer risk families. *Breast Cancer Research and Treatment*, **2012**, 136, 869-74	4.4	11

105	Androgen receptor CAG repeat size is associated with stress fracture risk: a pilot study. *Clinical Orthopaedics and Related Research*, **2011**, 469, 2925-31	2.2	11
104	Analysis of BRCA1/BRCA2 genesQcontribution to breast cancer susceptibility in high risk Jewish Ashkenazi women. *Familial Cancer*, **2009**, 8, 127-33	3	11
103	Candidate gene analysis in israeli soldiers with stress fractures. *Journal of Sports Science and Medicine*, **2012**, 11, 147-55	2.7	11
102	Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers. *European Journal of Human Genetics*, **2018**, 26, 382-386	5.3	10
101	Germline mutational analysis of presenilin 1 and APP genes in Jewish-Israeli individuals with familial or early-onset Alzheimer disease using denaturing gradient gel electrophoresis (DGGE). *European Journal of Human Genetics*, **1998**, 6, 176-80	5.3	10
100	p53 and WAF1 polymorphisms in Jewish-Israeli women with epithelial ovarian cancer and its association with BRCA mutations. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2000**, 107, 849-54	3.7	10
99	Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer. *Israel Medical Association Journal*, **2007**, 9, 791-6	0.9	10
98	Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2015**, 150, 631-5	4.4	9
97	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
96	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. *British Journal of Cancer*, **2018**, 118, 266-276	8.7	9
95	Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families. *Journal of Investigative Dermatology*, **2016**, 136, 1066-1069	4.3	9
94	The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations. *Breast Cancer Research and Treatment*, **2018**, 172, 151-157	4.4	9
93	Haplotype of the C61G BRCA1 mutation in Polish and Jewish individuals. *Genetic Testing and Molecular Biomarkers*, **2009**, 13, 465-9	1.6	9
92	Randomized controlled trial of Inquiry-Based Stress Reduction (IBSR) technique for BRCA1/2 mutation carriers. *Psycho-Oncology*, **2015**, 24, 726-31	3.9	8
91	Germline Mutations in Familial Papillary Thyroid Cancer. *Endocrine Pathology*, **2020**, 31, 14-20	4.2	8
90	The genetic history of Cochin Jews from India. *Human Genetics*, **2016**, 135, 1127-43	6.3	8
89	Next generation sequencing for newborn screening: are we there yet?. *Genetical Research*, **2015**, 97, e17	1.1	8
88	Inherited predisposition to breast and ovarian cancer in non-Jewish populations in Israel. *Breast Cancer Research and Treatment*, **2017**, 166, 881-885	4.4	8

87	Somatic mutation analysis of the APP and Presenilin 1 and 2 genes in Alzheimer disease brains. *Journal of Neurogenetics*, **1998**, 12, 55-65	1.6	8
86	Adrenal tumors in BRCA1/BRCA2 mutation carriers. *American Journal of Medical Genetics Part A*, **2001**, 98, 277-9		8
85	Cell phone use is associated with an inflammatory cytokine profile of parotid gland saliva. *Journal of Oral Pathology and Medicine*, **2016**, 45, 682-686	3.3	8
84	COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases. *Academic Radiology*, **2021**, 28, 1191-1197	4.3	8
83	Genotyping of geographically diverse Druze trios reveals substructure and a recent bottleneck. *European Journal of Human Genetics*, **2015**, 23, 1093-9	5.3	7
82	The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel. *Breast Cancer Research and Treatment*, **2018**, 167, 697-702	4.4	7
81	Trends in the incidence of primary brain, central nervous system and intracranial tumors in Israel, 1990-2015. *Cancer Epidemiology*, **2018**, 56, 6-13	2.8	7
80	Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates. *Journal of Gynecologic Oncology*, **2017**, 28, e61	4	7
79	Novel candidate genes putatively involved in stress fracture predisposition detected by whole-exome sequencing. *Genetical Research*, **2014**, 96, e004	1.1	7
78	The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer. *Familial Cancer*, **2012**, 11, 243-7	3	7
77	The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 132, 1119-26	4.4	7
76	Mutational analysis of hMsh6 in Israeli HNPCC and HNPCC-like families. *Familial Cancer*, **2005**, 4, 291-4	3	7
75	Non-Hodgkin lymphoma complicating acute lymphoblastic leukemia in remission. *Medical and Pediatric Oncology*, **1988**, 16, 132-4		7
74	Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?. *Breast* , **2020**, 49, 81-86	3.6	7
73	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7
72	Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. *Journal of Clinical Oncology*, **2016**, 34, e61-7	2.2	6
71	Performing and Declining PGD: Accounts of Jewish Israeli Women Who Carry a BRCA1/2 Mutation or Partners of Male Mutation Carriers. *Journal of Genetic Counseling*, **2017**, 26, 1070-1079	2.5	6
70	The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients. *Breast Cancer Research and Treatment*, **2019**, 178, 231-237	4.4	6

69	Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?. *Breast Cancer Research and Treatment*, **2012**, 132, 669-73	4.4	6
68	The P1812A and P25T BRCA1 and the 5164del4 BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews. *Genetic Testing and Molecular Biomarkers*, **2006**, 10, 200-7		6
67	The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers. *Familial Cancer*, **2004**, 3, 11-4	3	6
66	The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer. *Genetic Testing and Molecular Biomarkers*, **2000**, 4, 403-7		6
65	Malignant peritoneal mesothelioma: long-term spontaneous clinical remission. *Medical and Pediatric Oncology*, **1991**, 19, 325-8		6
64	Streptococcus bovis bacteremia and underlying gastrointestinal neoplasms. *Medical and Pediatric Oncology*, **1986**, 14, 313-5		6
63	Long-term remission of disseminated parathyroid cancer following immunotherapy. *Endocrine*, **2020**, 67, 204-208	4	6
62	Colorectal and Endometrial Cancer Risk and Age at Diagnosis in BLMAsh Mutation Carriers. *Israel Medical Association Journal*, **2017**, 19, 365-367	0.9	6
61	Differential analysis of mutations in the Jewish population and their implications for diseases. *Genetical Research*, **2017**, 99, e3	1.1	5
60	Radiation-Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 353-359	4	5
59	Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations. *Familial Cancer* , **2009**, 8, 473-8	3	5
58	Mutation analysis of the MEN1 gene in Israeli patients with MEN1 and familial isolated hyperprolactinemia. *Human Mutation*, **2000**, 16, 269	4.7	5
57	Mutational analyses of candidate genes in human squamous cell carcinomas. *Laryngoscope*, **1999**, 109, 661-3	3.6	5
56	Exclusion of the phosphoinositide-specific phospholipase C beta 3 (PLCB3) gene as a candidate for multiple endocrine neoplasia type 1. *Human Genetics*, **1997**, 99, 130-2	6.3	5
55	Primary Peritoneal Serous Carcinoma in Men: A Rare and Non--associated Entity. *Anticancer Research*, **2017**, 37, 3069-3072	2.3	5
54	Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms. *Breast Cancer Research and Treatment*, **2019**, 176, 165-170	4.4	4
53	Activating genomic alterations in the Gs alpha gene (GNAS) in 274 694 tumors. *Genes Chromosomes and Cancer*, **2020**, 59, 503-516	5	4
52	Mutational analysis of candidate genes in Israeli male breast cancer cases. *Breast Cancer Research and Treatment*, **2018**, 170, 399-404	4.4	4

51	DNA Base-Excision Repair Genes OGG1 and NTH1 in Brazilian Lung Cancer Patients. *Molecular Diagnosis and Therapy*, **2015**, 19, 389-95	4.5	4
50	FMR1 CGG allele length in Israeli BRCA1/BRCA2 mutation carriers and the general population display distinct distribution patterns. *Genetical Research*, **2014**, 96, e11	1.1	4
49	SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women. *Familial Cancer*, **2009**, 8, 135-44	3	4
48	Clinical Characteristics and Prognosis of Gastric Cancer Patients with Germline Mutations: Report of Ten Cases and a Literature Review. *OncoTargets and Therapy*, **2020**, 13, 11637-11644	4.4	4
47	Whole-exome identifies RXRG and TH germline variants in familial isolated prolactinoma. *Cancer Genetics*, **2016**, 209, 251-7	2.3	4
46	Common Susceptibility Loci for Male Breast Cancer. *Journal of the National Cancer Institute*, **2021**, 113, 453-461	9.7	4
45	Locoregional Treatments and Ipsilateral Breast Cancer Recurrence Rates in BRCA1/2 Mutation Carriers. *International Journal of Radiation Oncology Biology Physics*, **2021**, 109, 1332-1340	4	4
44	Impact of Ethnicity on Somatic Mutation Rates of Pancreatic Adenocarcinoma. *In Vivo*, **2018**, 32, 1527-1531	2.3	4
43	Molecular and immunohistochemical analyses of uveal melanoma patient cohort. *Melanoma Research*, **2019**, 29, 248-253	3.3	3
42	Malignant phenotype and two SDHD mutations in a family with paraganglioma syndrome type 1. *Genetical Research*, **2015**, 97, e3	1.1	3
41	Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study. *Cancer Biomarkers*, **2020**, 28, 269-273	3.8	3
40	The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2011**, 126, 521-7	4.4	3
39	Mutational analysis of the hMSH6 gene in familial and early-onset colorectal and endometrial cancer in Israeli patients. *Genetic Testing and Molecular Biomarkers*, **2002**, 6, 323-6		3
38	The spectrum of tumors harboring BAP1 gene alterations. *Cancer Genetics*, **2021**, 256-257, 31-35	2.3	3
37	Germline variant in is a novel candidate gene in familial pheochromocytoma. *Genetical Research*, **2020**, 102, e3	1.1	2
36	Abnormal Findings Detected by Multi-modality Breast Imaging and Biopsy Results in a High-risk Clinic. *Clinical Breast Cancer*, **2018**, 18, e695-e698	3	2
35	De novo mutation in MEN1 is not associated with parental somatic mosaicism. *Endocrine-Related Cancer*, **2017**, 24, L1-L3	5.7	2
34	A novel MSH2 germline mutation in a Druze HNPCC family. *Familial Cancer*, **2008**, 7, 135-9	3	2

33	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
32	The rate of the recurrent MSH6 mutations in Ashkenazi Jewish breast cancer patients. *Cancer Causes and Control*, **2019**, 30, 97-101	2.8	2
31	Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants. *Breast Cancer Research and Treatment*, **2020**, 181, 445-453	4.4	2
30	Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2021**, 185, 391-399	4.4	2
29	Are VNTRs co-localizing with breast cancer-associated SNPs?. *Breast Cancer Research and Treatment* , **2018**, 168, 277-281	4.4	1
28	The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. *Cancer Genetics*, **2016**, 209, 283-4	2.3	1
27	Co-occurrence of p.Gly111fs and p.Arg16His Variants in Familial MEN1 Phenotype. *Anticancer Research*, **2018**, 38, 3683-3687	2.3	1
26	Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 131, 981-5	4.4	1
25	The m2 and m4 polymorphisms in CYP1A1 by NcoI digest-revision of detection method. *Human Mutation*, **2000**, 15, 120	4.7	1
24	A germline mutation in the von Hippel-Lindau disease gene (L178Q) detected by denaturing gradient gel electrophoresis in a large Jewish-Yemenite family. *Human Mutation*, **1999**, 14, 448	4.7	1
23	Chemosensitivity and clinical characteristics of pancreatic malignancies in BRCA mutation carriers.. *Journal of Clinical Oncology*, **2013**, 31, 278-278	2.2	1
22	De novo pathogenic germline variant in PALB2 in a patient with pancreatic cancer. *Familial Cancer*, **2020**, 19, 193-196	3	1
21	Re-evaluating the pathogenicity of the c.783+2T>C BAP1 germline variant. *Human Mutation*, **2021**, 42, 592-599	4.7	1
20	Genetic association of the PERIOD3 (PER3) Clock gene with extreme obesity. *Obesity Research and Clinical Practice*, **2021**, 15, 334-338	5.4	1
19	Genetic Analysis of Brazilian Patients with Gallbladder Cancer. *Pathology and Oncology Research*, **2019**, 25, 811-814	2.6	1
18	Automated Breast Volumetric Sonography Compared with Magnetic Resonance Imaging in Jewish BRCA 1/2 Mutation Carriers. *Israel Medical Association Journal*, **2016**, 18, 609-612	0.9	1
17	Accuracy of Risk Prediction Models for Breast Cancer and Mutation Carrier Probabilities in Israel. *Anticancer Research*, **2018**, 38, 4557-4563	2.3	0
16	Colonic Adenomas Do Not Cosegregate with the I1307K APC Missense Mutation in an Israeli Non-Ashkenazi Family. *Digestive Diseases and Sciences*, **2005**, 50, 52-55	4	0

15	Re-evaluating cancer risks associated with the CHEK2 p.Ser428Phe Ashkenazi Jewish founder pathogenic variant. *Familial Cancer*, **2021**, 1	3	0
14	Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention. *Menopause*, **2020**, 27, 82-87	2.5	0
13	Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population. *Cancer*, **2021**, 127, 3599-3604	6.4	0
12	Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications. *Breast Cancer Research and Treatment*, **2021**, 188, 685-694	4.4	0
11	Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations. *Breast Cancer Research and Treatment*, **2021**, 186, 259-263	4.4	0
10	Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients. *Breast Journal*, **2021**, 27, 441-447	1.2	0
9	Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers. *Fertility and Sterility*, **2021**, 116, 538-545	4.8	0
8	Effect of Inquiry-Based Stress Reduction on Well-being and Views on Risk-Reducing Surgery Among Women With BRCA Variants in Israel: A Randomized Clinical Trial.. *JAMA Network Open*, **2021**, 4, e2139670	10.4	0
7	A neutral polymorphism (c1088C>T) in the estrogen receptor detected by DGGE. *Human Mutation*, **1999**, 13, 507-507	4.7	
6	Overall survival and clinical characteristics of BRCA germline/somatic cholangiocarcinoma (CCA).. *Journal of Clinical Oncology*, **2016**, 34, 244-244	2.2	
5	Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors. *Familial Cancer*, **2021**, 20, 189-194	3	
4	Risk-reducing salpingo-oophorectomy and breast cancer incidence among BRCA-mutation carriers.. *Journal of Clinical Oncology*, **2021**, 39, 10548-10548	2.2	
3	Genetic testing for assessment of lynch syndrome in young patients with polyps. *Digestive and Liver Disease*, **2021**, 53, 1640-1646	3.3	
2	Abstract P2-09-16: Clinicopatological features and outcome of breast cancer in CHEK2 germline mutation carriers. *Cancer Research*, **2022**, 82, P2-09-16-P2-09-16	10.1	
1	Population-based screening of Uruguayan Ashkenazi Jews for recurrent BRCA1 and BRCA2 pathogenic sequence variants.. *Molecular Genetics & Genomic Medicine*, **2022**, e1928	2.3	